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Abstract: With the rise of global migration, international trade, and global environmental challenges
such as climate change, it is not surprising that the interactions between humans and other animals are
shifting. Salient infectious diseases, such as malaria and HIV (which have high burdens of disease),
attract sophisticated public health frameworks and funding from global/regional organisations,
such as the WHO. This unfortunately detracts attention from the many emerging zoonoses that fall
under the radar as neglected tropical diseases (NTDs). This review considers the available literature
and the attribution of burden of disease to the most insidious NTDs and recommends which five
are deserving of policy prioritisation. In line with WHO analyses of NTDs, intestinal nematode
infections, leishmaniasis, schistosomiasis, and lymphatic filariasis should be prioritised, as well as
the burden of disease of cryptosporidiosis, which is largely underestimated. Both monitoring and
treatment/prevention control methods for cryptosporidiosis are suggested and explored.
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When considering global burden of disease (BOD) of infectious origin, it is usually certain
‘poster-child’ diseases that come to mind, such as tuberculosis, malaria, avian influenza, and HIV. This
is reflected in global prevention strategies and allocation of resources [1]; however, it also means that
there is a large body of infectious diseases called neglected tropical diseases (NTDs) that may fall
below the global public health radar and either continue untreated or pose possible pandemic risk [2].
Specifically, zoonotic parasitic infections are of interest, considering the shifting interactions between
humans and other animals as well as global trade and agriculture—with the rise of One Health as a
public health discipline within the past decade [3,4]. This literature review will consider emerging
parasitic zoonoses that fall into the category of NTDs and contribute the most to the global BOD. Upon
outlining the relevant literature and presenting the top five zoonotic parasitic diseases in terms of
global BOD, an integrated control program will be suggested for cryptosporidiosis, which is largely
neglected in salient public health literature and public health policy.
On the topic of emerging parasitic zoonoses, a piquing observation was made by Thompson
and Deplazes (2011): ‘In the context of emerging diseases, parasite zoonoses figure prominently,
undoubtedly because of the shifting interactions between humans and other animals.’ [5]. Regarding
the sheer number of emerging infectious diseases, the use of ‘prominently’ is definitely accounted for,
with over 60% of around 400 identified infectious diseases since 1940 being zoonotic [4]. However, it is
important to view this in light of global BOD (which is often underestimated for these diseases) and
the relative methods of transmission of these zoonoses. For example, certain zoonotic parasites may
affect humans as incidental hosts (e.g., toxoplasmosis), where infection is dependent upon human
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behaviour/interaction with the definite hosts, while other zoonotic parasites readily infect humans
and are more easily spread through environmental modes such as rain runoff, flooding, vectors, and
aerosol spread [6].
For the purposes of this review, the global BOD framework proposed by Hotez et al. (2014) [7]
will be used to explore the top five parasitic zoonoses (Table 1): (i) cryptosporidiosis; (ii) intestinal
nematode infections (INI); (iii) leishmaniasis; (iv) schistosomiasis; and (v) lymphatic filariasis (LF).
Despite listing BOD calculations in terms of disability adjusted life years (DALYs), which can further
be broken down into components of years lived with disability (YLD) and years lost to premature
mortality (YLL) [8], the analysis done by Hotez et al. (2014) through the World Health Organization
(WHO) is not without its criticisms [7]. Briefly, criticisms of the analysis include existing gaps in data
(especially in poorer parts of the world) and estimates of population health being prone to differing
cultural frameworks—somewhat obscuring the extent of the BOD due to a given disease [9]. A full
critique of that analysis is beyond the scope of this review; however, what remains important to
remember is the economic limitations of instituting public health prevention strategies on a global
scale and how resource management is necessary when dealing with a largely neglected subset of
global infectious diseases [9].
Table 1. Summary of burden of disease (BOD) floor estimates of 5 most salient neglected tropical
zoonotic parasitic diseases.
Rank Disease BOD (million DALYs)
1 Cryptosporidiosis 8.37
2 Intestinal nematode infections 5.16
3 Leishmaniasis 3.32
4 Schistosomiasis 3.31
5 Lymphatic filariasis 2.78
1. Cryptosporidiosis
Possibly the largest critique of the WHO’s analysis of NTDs is the choice to not include
cryptosporidiosis in the NTD category despite it contributing significantly to the global BOD, with
an estimate of 8.37 million DALYs according to 2010 data, which may be an underestimation in
itself [7]. Recent evidence suggests that in the developed world, cryptosporidium diagnoses may
reflect somewhere as low as 1% of true prevalence, with this being even lower in the developing
world [10]. Considering the global distribution of protozoa of the Cryptosporidium genus and that
immune-compromised patients and children are at risk of developing cryptosporidiosis, this suggests
a greater BOD when paired with its diagnostic evasiveness [11]. In recent studies, estimates show
that up to a quarter of children with diarrhoea are co-morbidly infected with cryptosporidium,
which is associated with longer durations of diarrhoea, malnutrition, higher mortality rates, and
immune-compromise [12].
According to the Centers for Disease Control and Prevention (CDC), transmission of C. parvum
and C. hominis (the two primary species affecting humans) occurs mainly through drinking or
eating contaminated water/food where thick-walled oocysts are ingested, allowing further parasite
maturation in the intestines and reproduction into auto-infective thin-walled oocysts and thick-walled
oocysts that pass through faeces into the environment [13]. Interestingly, this life cycle is not unique to
humans with other Cryptosporidium spp. infecting essentially all mammals, including those in close
domestic proximity to humans [13]. However, according to a recent study, no significant difference in
BOD was found between households that used bottled water and those that used tap water, suggesting
that the primary method of spread lies elsewhere [14]. When paired with higher levels of oocysts
(which are quite resistant to chlorination attempts) in surface water at the end of rainy seasons, seasonal
patterns in cryptosporidiosis suggest that rainwater-runoff in areas with poor infrastructure are perfect
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breeding grounds for Cryptosporidium spp. due to the hot and humid environment, so there is an
increased risk of infection [15]. There is much we do not know about the extent of cryptosporidiosis
globally; however, if the BOD is to be lowered and improved, accessible diagnostic methods must be
made available globally (with animals also tested) [11]. Treatments targeting the reasons for infection,
such as immunocompromised/AIDS or INIs, should also be prioritised and supplemented with
antiparasitic therapy [11].
2. Intestinal Nematode Infections (INI)
DALY analyses of the global BOD of NTDs have systematically demonstrated the dominance and
wide epidemiological spread of INIs with an estimated 5.19 million DALYs [7]. Of these, the majority
are accounted for by hookworm diseases (3.23 million), followed by ascariasis (1.32 million), then by
trichuriasis (0.64 million) [7]. Interestingly in the WHO analysis, strongyloidiasis was not included in
the INI figure, which may result in a severe underestimation of the total BOD arising from nematodes.
Regarding global prevalence, INIs are most prevalent in Asia with roughly 67% of cases; however,
incidence rates controlled for country population are quite unvaried between major global regions [15].
The burden of INIs seems to vary greatly within major global regions, which makes sense considering
the methods by which these diseases are spread—water runoff, rain, animals, and human migration
amidst inadequate public sanitation and infrastructure [16].
The lifecycle of soil-transmitted helminths is important to consider, as the eggs of the helminth
are passed from the definitive host into the environment at the infective stage [11,16,17]. The larvae of
Strongyloides stercoralis, unlike other soil-transmitted helminths, are passed in faeces at the infective
stage [11,16,17]. The pathological sequelae of Ascaris lumbricoides and Trichuris trichiura primarily
involve symptomatic infection (and associated immunocompromise), wasting, and abdominopelvic
problems, whereas the added complication of anaemia (from bleeding) is present in hookworm
infections [17]. Maturation of eggs/larvae in the environment differ between helminthic species with
some species requiring eggs to hatch into larvae (non-infective eggs) and others requiring the ingestion
of eggs for maturation into adult worms; what remains constant is the need for soil/environmental
infestation of eggs/larvae in order to complete the life cycle [17]. Eggs can survive from months to
years in the environment, and with the addition of mammalian hosts the spread of a wider variety of
zoonoses is made possible, with humans being incidental hosts of nematodes such as in the life cycle
of Trichinella spp. [17].
3. Leishmaniasis
Leishmaniasis accounts for a significant proportion of global BOD from NTDs with an estimate of
3.32 million DALYs according to Hotez et al. (2014) [7]. Most tropical countries are at risk of endemic
leishmaniasis with spread being likely, considering that the primary vector is the phlebotomine sandfly,
which has over 30 species and does not respect international country borders [18]. A large problem in
Leishmania spp. endemic countries is co-infection with other NTDs, such as HIV, which act together to
produce immunocompromise and increased levels of morbidity associated with leishmaniasis [18].
Much like Anopheles spp. malaria vectors, phlebotomine sandfly distribution is limited to areas above a
certain temperature (in this case 15.6 ◦C), and with global warming ultimately pushing the latitudinal
tropical borders further apart, the risk of spread of leishmaniasis via sandflies to naïve countries is a
real possibility [19].
The most common form of leishmaniasis is cutaneous and presents with skin sores, which can be
painful and ultimately result in debilitating social isolation and decreased quality of life (sometimes
leading to mucosal leishmaniasis) similar to lymphatic filariasis [20]. Visceral leishmaniasis, also
significantly present in the tropics, has a much higher morbidity rate than cutaneous resulting in
multiple organ failure as well as anaemia, leukopenia, and thrombocytopenia [20]. Regarding the
spread of leishmaniasis, depending on the region of the world and strain of Leishmania spp. the
parasitic life cycle can be propagated without the presence of humans, with rodents and dogs being
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able to act as reservoirs for the disease [20,21]. In regions where anthroponotic spread is prevalent,
treating individuals will help break the cycle of spread; however, with changing climates, increasing
human traffic, and increases in global population density, the prevalence of less common forms of
leishmaniasis without the need for anthropogenic spread could increase [20,21].
4. Schistosomiasis
Although schistosomiasis has a similar global BOD, as estimated by Hotez et al. (2014)
at 3.31 million DALYs, it has a significantly higher proportion of YLL % and higher global
prevalence [7]. Schistosoma japonicum, S. haematobium, and S. mansoni are the primary pathogens
of humans contributing to the majority of the global BOD. The geographic distribution lies primarily
in Africa/Caribbean/Middle East for S. mansoni and S. haematobium, and in Asia for S. japonicum.
In addition, the salient human schistosomes S. intercalatum and S. mekongi are primarily found in
Central-West Africa and Southeast Asia, respectively [22,23]. The vectors for all Schistosoma spp. are
types of snails, which are infected by Schistosoma spp. miracidia that hatch in water following human
defecation or urination (for S. haematobium). These further develop within the snail into cercariae
(the infective forms), which are then released back into the water and directly infect the definitive
hosts when they comes into contact with them [22,23]. Of significance is the ability of S. mekongi and
S. japonicum to live in animal reservoirs including many agricultural/domestic animals such as dogs,
cats, pigs, goats, and horses [22,23].
With the increasing reliance on local agricultural produce and a lack of adequate infrastructure
and sanitation in parts of the globe most affected by schistosomiasis, the threat of spread of the disease
should be considered with surveillance/monitoring of infection in populations, snail xenodiagnoses,
and adequate treatment regimens [22,24]. There are two main stages of schistosomiasis—the
chronic and acute stages—with the acute stage usually presenting in pathogen-naïve persons as
a cluster of symptoms known as Katayama syndrome [22,23]. Over time, the worms take refuge
in the mesenteric venules/hepatic portal system, causing crippling pathological sequelae ranging
from organomegaly/cirrhosis to gastrointestinal bleeding (haematuria for S. haematobium) and
anaemia [22,23]. A hallmark feature of schistosomiasis often overlooked by BOD estimates is the
long-lasting effects of the illness on persons even long after de-worming [22,25]. Growth stunting,
cognitive impairment, and permanent organ damage/increased risks of numerous cancers all add
up to nearly double the global BOD for an already underestimated disease, according to Colley et al.
(2014) [22,23,25].
5. Lymphatic Filariasis (LF)
At the bottom of the top five list by global BOD, as calculated by Hotez et al. (2014), is
LF—accountable for approximately 2.78 million DALYs, mostly through YLDs [7]. Although the
three pathogenic helminths responsible for LF, Brugia malayi, Brugia timori, and Wuchereria bancrofti, are
technically nematodes, the fact that they are transmitted by mosquitos at the larval stage warrants
their separate treatment to the majority of soil-transmitted nematodes [26]. The disease is found
within the tropics, specifically in East/Southeast Asia, Oceania, Africa, and South America, with many
different mosquito species able to function as vectors including Culex spp., Anopheles spp., Aedes spp.,
Mansonia spp., and Coquillettidia juxtamansonia [26,27]. This wide range of possible vectors brings with
it a very salient risk of future LF outbreaks and spread beyond the currently endemic areas if proper
public health systems and prophylactic measures are not taken to control spreading vectors (due to
urbanisation and climate change) and prevent infection of at-risk persons [27].
The main pathophysiology of LF is linked to the L3 stage of the worm larvae, which further
develop into adults and reside in the human lymphatics leading to lymphoedema, hydrocele, and an
immunocompromised status resulting in increased opportunistic infections (which leave fibrotic tissue
and thus elephantiasis), the majority of which account for the global BOD [26,27]. LF, unlike the other
diseases mentioned in this review, quite rarely presents acutely, with the vast majority of sufferers
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living with chronic LF. However, the majority of the burden stems from the decrease in quality of life
through psychiatric, social, and chronic suffering complications associated with the infection [7,26].
This is a double-edged sword, as although the rate of morbidity of LF is not high, this in turn means
that governments and relevant stakeholders are less likely to prioritise LF treatment when other more
apparent diseases, such as malaria and even leishmaniasis or schistosomiasis are present.
6. Control Methods for Cryptosporidiosis
Having considered five of the NTDs responsible for the greatest global BOD that should be
prioritised by global stakeholders, the WHO, and nation-states, it is vital to consider the pragmatism
of implementing any control or prevention strategies to curb the associated BOD. For example, LF
elimination programs that originated as early as the year 2000 are already underway with mass
drug administration and DEC-medicated salt as major programs for elimination [27]. The other
zoonoses mentioned (leishmaniasis, schistosomiasis and INIs) currently all fall within the WHO’s NTD
framework and coordinated multinational approaches to control these are either in place (de-worming
strategies for INIs) or are planned for the near future [7,11]. What is key about the existing NTD
framework, is that it inherently acts to prioritise certain diseases within the public health sphere
for monitoring and surveillance, without which even the most effective treatment/control strategies
would not be effective [11]. As such, cryptosporidiosis control and strategy development should be
prioritised within the existing WHO NTD framework.
As outlined above, the detection of cryptosporidial infection is difficult for a number of
reasons, many of which are caused by or compounded by low-resource settings in the most afflicted
countries. The following domains of infection control will be outlined for cryptosporidiosis with
recommendations made at the end (Table 2): (i) Monitoring/surveillance; (ii) treatment and prevention.
Table 2. Summary of control methods for cryptosporidiosis [14].
Control Methods for Cryptosporidiosis
Type of control method Method used Notes
Monitoring/Surveillance
Microscopy
Low sensitivity, but often the only option in
low-resource settings. Sensitivity significantly higher
with fluorescent antibody staining.
Antigen detection
Expensive for poorer countries, however readily
available commercial test kits with reasonable
(70%+) sensitivity.
Nucleic acid
amplification (ANA)
Good for ruling out infection, however a low positive
predictive value renders it not suitable as a first line
for diagnosis.
Serology
Limited to laboratories with no commercial kits
available—useful for population surveillance
of cryptosporidiosis.
Xenodiagnosis
Underutilised method of surveillance which may be
useful in areas suspected of harbouring disease
vectors but are lacking in clinical/epidemiological
surveillance of zoonotic disease.
Treatment/Prevention
Nitazoxanide
Useful for treatment of cryptosporidiosis in non-HIV
patients, however it has limited usefulness for
immunocompromised patients.
Cryptosporidium vaccine
Evidence suggests development of a vaccine is
possible, however it will likely take a significant
amount of time to complete.
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7. Monitoring/Surveillance
As previously mentioned, even with the best technology available the vast majority of
cryptosporidium infections (which may be subclinical) go undetected, lying dormant until the host’s
body is immunocompromised enough for an acute infection [11,28]. Detection of Cryptosporidium spp.
can be done through four main methods including microscopy, antigen detection, nucleic acid
amplification (ANA), and serological methods of stool samples; however, usually only microscopy is
available in low-resource settings [29,30]. Considering the relative low sensitivity (70–80% with
modified acid-fast stains) and human error component of microscopy, this becomes a problem
when public health policy and control methods are based on estimates using this technology [11,30].
In Europe/USA, immunofluorescence microscopy, as well as ANA, are used quite readily; however,
serological assays or PCR (which are more cost-laden) are a must when it comes to accurate
epidemiological analysis of the global cryptosporidium problem [11,30]. Without adequate economic
and socio-political investment in monitoring cryptosporidiosis, much progress will not be made,
therefore it is recommended that national data are kept updated, with mandatory reporting of
cryptosporidiosis by health practitioners.
The primary methods of spread of Cryptosporidium spp. is through the pathogens living in
bodies of water that then come into contact with humans through direct ingestion by drinking or
washing food with infected water [13]. In fact, there does not seem to be an increased risk of acquiring
cryptosporidiosis from municipal drinking water—which goes through sterilization processes and
pathogen testing—suggesting that the parasites of interest are found elsewhere [19]. The seasonal
patterns of cryptosporidiosis also suggest that rainfall/flooding play a large part in the spread of
the disease, with mammal reservoirs playing a large part in the spread [11,13,14]. What is worrying
about these trends is the relative lack of consensus regarding the spread of Cryptosporidium spp., with
xenodiagnoses being almost non-existent in low-mid income countries [11]. In terms of improving
surveillance/monitoring of cryptosporidiosis globally, the first step would be to include this disease
within the WHO’s Global Burden of Disease framework [7] to increase international awareness of the
BOD associated with Cryptosporidium spp. Furthermore, xenodiagnosis has been a somewhat neglected
tool for the prevention of protozoan spread and should be conducted whenever possible before
animals are transported throughout agricultural trade [11]. This extends to the proper quarantine
of food products for import/export and cooking food whenever possible, especially considering
that Cryptosporidium spp. can survive cold temperatures, such as in refrigerators for up to several
weeks [11,31].
8. Treatment and Prevention
Assuming adequate monitoring systems are in place for cryptosporidiosis, public health systems
at a national level can react in one of two ways: (a) treatment (generally a short-term solution) and/or
(b) prevention.
(a) Treatments in the form of antiparasitic medications are usually not effective for populations
most at risk of contracting cryptosporidiosis en masse, such as those with HIV comorbidities or the
elderly. As such, treatments for cryptosporidiosis tend to be complicated and vary from patient
to patient, making successful public health interventions such as the LF elimination MDAs less
likely to succeed [11,32,33]. For non-HIV infected patients, nitazoxanide has been shown to be an
effective treatment for cryptosporidiosis and is relatively cheap at roughly $US10 per prescription
dose [11,32,33]. However, it is the HIV-infected patients and subclinically infected children for which
no real effective treatment has been developed [11]. Further research into novel drugs suitable for use
in infants and HIV-immunocompromised patients is vital if any effective mass treatment initiatives are
to take place to reduce the global BOD of cryptosporidiosis [11,34].
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(b) Currently a vaccine for cryptosporidiosis does not exist; however, several factors have
been identified suggesting that this would be a possibility due to the involvement of innate
and adaptive immune processes including: (a) persons in endemic areas being less prone to
re-infection; (b) prior infection requiring a higher infectious dose for re-infection; (c) increased
severity of infection in immunocompromised patients [11,35]. At present, vaccine development
is underway; however, it is likely to take a substantial amount of time considering the sheer number of
antigens required for identification, as well as the relative immunological individuality of different
Cryptosporidium spp. [11,35].
Ultimately, regardless of whether monitoring or treatment/prevention is being considered, more
global funding and attention is required in order to realize any of these control strategies. The
phenomenal cooperation of albendazole/ivermectin drug manufacturers with not-for-profits and state
actors in the elimination of LF is a great model for diseases such as cryptosporidium, and as such,
primary focus should fall on raising awareness of cryptosporidium as a global problem that could
affect those in the developed world through food/agricultural trade [27]. The zoonotic aspects of
cryptosporidiosis cannot be ignored, and further cooperation between public health professionals and
those in agricultural/veterinary sectors should be encouraged.
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